Usage and Distribution for Commercial Purposes Requires Written Permission. Pregnant Woman with Atypical Hemolytic Uremic Syndrome Delivered a Healthy Newborn under Eculizumab Treatment Demir Et Al.: Pregnant Woman with Atypical Hemolytic Uremic Syndrome Delivered a Healthy Newborn under Eculizumab
Usage and Distribution for Commercial Purposes Requires Written Permission. Pregnant Woman with Atypical Hemolytic Uremic Syndrome Delivered a Healthy Newborn under Eculizumab Treatment Demir Et Al.: Pregnant Woman with Atypical Hemolytic Uremic Syndrome Delivered a Healthy Newborn under Eculizumab
复制标题
DOI：
--
复制
发表时间：
--
期刊：
影响因子：
--
通讯作者：
E. Demir;H. Yazıcı;Y. Ozluk;I. Kílícaslan;A. Turkmen
中科院分区：
文献类型：
--
作者：
E. Demir;H. Yazıcı;Y. Ozluk;I. Kílícaslan;A. Turkmen
Keywords Pregnancy-associated thrombotic microangiopathy · Pregnancy-associated atypical hemolytic uremic syndrome · Eculizumab Abstract Pregnancy-associated thrombotic microangiopathy is a very rare condition; however, it significantly increases fetal or maternal morbidity and mortality. Pregnancy may trigger atypical hemolytic uremic syndrome (aHUS) or thrombotic thrombocytopenic purpura. The risk for pregnancy-associated aHUS is highest during the second pregnancy. The outcome is usually poor with 50–60% mortality; renal dysfunction and hypertension are the rule in those who survive the acute episode. After the development of complement regulation mechanisms and aHUS pathogenesis, eculizumab has been widely used as a first-line treatment in aHUS. Eculi-zumab has been produced to minimize immunogenicity and Fc-mediated functions, including recruitment of inflammatory cells and complement activation, and using eculizumab in first-line treatment improves kidney function. Recent studies showed that early diagnosis and 144 rapid use of eculizumab in first-line treatment improve outcomes. We demonstrate a case with pregnancy-triggered aHUS occurring in the second trimester, who was successfully treated and delivered a healthy baby under eculizumab treatment.
